{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059518","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.542717+00:00","generated_at":"2026-06-02T01:11:18.289951+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SeaStar Medical Q1 net loss $12.7M, cash rises to $5M; Quelimmune launch imminent","bullets":["Net loss $12.7M ($0.19 per share) vs $7.1M ($0.54) in Q1 2023; no revenue recorded.","Cash and cash equivalents $5.0M as of March 31, 2024, up from $176K at Dec 31, 2023.","Quelimmune Pediatric received FDA approval in Feb 2024; initial sales expected in coming weeks at five children's hospitals.","NEUTRALIZE-AKI adult trial enrolled 31 subjects at eight sites; regulatory approval expected H2 2025.","January 2024 $9M at-the-market offering and appointment of David A. Green as CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059518","json":"https://secwatch.observer/filing/0000950170-24-059518.json","markdown":"https://secwatch.observer/filing/0000950170-24-059518.md","text":"https://secwatch.observer/filing/0000950170-24-059518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024059518/0000950170-24-059518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024059518/icu-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:11:18.289951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09d2e1127fa9645bc62294ae2801f7fc771dde56","claim":"SeaStar Medical Holding Corp reported financial results for the three months ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, SeaStar Medical Holding Corporation (the “Company”) issued a press release announcing its financial condition and results of operations for the fiscal quarter-ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831868/000095017024059518/0000950170-24-059518-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}